Clinical Trials Logo

Eczema clinical trials

View clinical trials related to Eczema.

Filter by:

NCT ID: NCT05372419 Active, not recruiting - Atopic Dermatitis Clinical Trials

A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color

ADmirable
Start date: January 12, 2023
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atopic dermatitis (AD) and skin of color.

NCT ID: NCT05369403 Active, not recruiting - Atopic Dermatitis Clinical Trials

A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab

ADapt
Start date: December 19, 2022
Phase: Phase 3
Study type: Interventional

The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) previously treated with Dupilumab.

NCT ID: NCT05318300 Active, not recruiting - Atopic Dermatitis Clinical Trials

Evaluation of an Adapted Formula on Atopic Dermatitis.

Start date: May 24, 2022
Phase: N/A
Study type: Interventional

The aim of this study is to show the efficiency of a new infant formula containing fiber on the management of moderate to severe atopic dermatitis.

NCT ID: NCT04717310 Active, not recruiting - Atopic Dermatitis Clinical Trials

Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis

MARBLE-23
Start date: December 30, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

This is a Randomized, Double-blind, Vehicle-Controlled, Seamless and Adaptive-designed Phase II/III Study to Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Adult Patients with Mild-to-Moderate Atopic Dermatitis. It will consist of phase II and phase III parts, phase II will be a dose-ranging part and phase III will be a pivotal study part.

NCT ID: NCT04643457 Active, not recruiting - Atopic Dermatitis Clinical Trials

A Study to Test the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants and in Study Participants With Atopic Dermatitis

Start date: November 27, 2020
Phase: Phase 1
Study type: Interventional

The purpose of the study is to investigate the safety and tolerability of single-ascending doses of UCB9741 administered by intravenous infusion or subcutaneous injection to healthy study participants and following repeat dosing at a single dose level in study participants with atopic dermatitis. Furthermore, the clinical efficacy outcome in study participants with atopic dermatitis after administration of UCB9741 by intravenous infusion will be investigated.

NCT ID: NCT04599946 Active, not recruiting - Child Development Clinical Trials

Goat Infant Formula Feeding and Eczema (the GIraFFE Study)

GIraFFE
Start date: January 8, 2021
Phase: N/A
Study type: Interventional

To determine the relative risk of developing atopic dermatitis in infants fed a study formula based on whole goat milk compared to infants a study formula based on cow milk protein.

NCT ID: NCT04512339 Active, not recruiting - Hand Eczema Clinical Trials

Dupilumab in Severe Chronic Hand Eczema

DUPSHE
Start date: August 1, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the efficacy of dupilumab in hand eczema patients with an inadequate response or intolerance to alitretinoin.

NCT ID: NCT04419584 Active, not recruiting - Atopic Dermatitis Clinical Trials

Evaluate the Efficacy of Using Modified Qing-Ying Decoction in Atopic Dermatitis Children

Start date: September 10, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

The study aims to evaluate the clinical efficacy and safety of the modified Qing-Ying Decoction (mQYD) for the treatment of subacute and chronic atopic dermatitis (AD) in children when compared to the placebo control through examining the clinical symptoms, quality of life, gut microbiome, and Chinese medicine body constitution. This is a parallel, randomized, placebo-controlled, double-blind clinical trial. Eligible subjects will be randomly allocated to receive oral mQYD granules or it's placebo granules. Subjects will have 12-week of treatment, and then a 4-week follow-up.

NCT ID: NCT04413942 Active, not recruiting - Atopic Dermatitis Clinical Trials

Evaluate Efficacy, PK, and Safety of FB825 in Adults With Atopic Dermatitis

Start date: March 10, 2020
Phase: Phase 2
Study type: Interventional

The study aims to evaluate the efficacy, improvement from baseline in Eczema Area and Severity Index (EASI) score, of multiple intravenous (IV) doses of FB825 in subjects with atopic dermatitis

NCT ID: NCT04392154 Active, not recruiting - Atopic Dermatitis Clinical Trials

Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

ADjoin
Start date: June 15, 2020
Phase: Phase 3
Study type: Interventional

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.